TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

2A.79 Tristram S et al. Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev 2007;20:
368-89.
2A.80 Harrison CJ et al. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including
serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
J Antimicrob Chemother 2009;63:511-9.
2A.81 Felmingham D et al. The Alexander project: the benefits from a decade of surveillance. J Antimicrob
Chemother 2005;56(suppl. S2):ii3-21.
2A.82 Janda JM et al. The genus Hafnia: from soup to nuts. Clin Microbiol Rev 2006;19:12-28.
2A.83 Stock I et al. Natural antimicrobial susceptibility patterns and biochemical identification of Escherichia
albertii and Hafnia alvei strains. Diagn Microbiol Infect Dis 2005;51:151-63.
2A.84 Boyanova L et al. Geographic map and evolution of primary resistance of Helicobacter pylori to antibacterial
agents. Expert Rev Anti Infect Ther 2010;8:59-70.
2A.85 Vakil N et al. Eradication therapy for Helicobacter pylori. Gastroenterology 2007;133:985-1001.
2A.86 Gisbert JP et al. Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter
2007;12(suppl. 2):50-8.
2A.87 Kusters JG et al. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19:449-60.
2A.88 Dubnov-Raz G et al. Invasive Kingella kingae infections in children: clinical and laboratory characteristics.
Pediatrics 2008;122:1305-9.
2A.89 Stock I et al. Natural antibiotic susceptibility of Klebsiella pneumoniae, Klebsiella oxytoca, Klebsiella
planticola, Klebsiella ornithinolytica and Klebsiella terrigena strains. J Med Microbiol 2001;50:396-
406.
2A.90 Botelho-Nevers E et al. Chronic nasal infection caused by Klebsiella rhinoscleromatis or Klebsiella
ozaenae: two forgotten infectious diseases. Int J Infect Dis 2007;11:423-9.
2A.91 Cannon JP et al. Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases.
Eur J Clin Microbiol Infect Dis 2005;24:31-40.
2A.92 Salminen MK et al. Lactobacillus bacteremia, species identification and antimicrobial susceptibility of
85 blood isolates. Clin Infect Dis 2006;42:e35-44.
2A.93 Pedro-Botet L et al. Legionella: macrolides or quinolones? Clin Microbiol Infect 2006;12(suppl.
3):25-30.
2A.94 Dunbar LM et al. Activity of telithromycin and comparators against isolates of Legionella pneumophila
collected from patients with community-acquired respiratory tract infections: PROTECT years 1-5.
Clin Microbiol Infect 2007;13:743-6.
2A.95 Stout JE et al. Comparative activity of quinolones, macrolides and ketolides against Legionella species
using in vitro broth dilution and intracellular susceptibility testing. Int J Antimicrob Agents 2005;
25:302-7.
2A.96 Garcia-Vidal C et al. Current clinical management of legionnaires‘ disease. Expert Rev Anti Infect
Ther 2006;4:995-1004.
2A.97 Panaphut T et al. Ceftriaxone compared with sodium penicillin G for treatment of severe leptospirosis.
Clin Infect Dis 2003;36:1507-13.
2A.98 Felmingham D et al. The Alexander project: the benefits from a decade of surveillance. J Antimicrob
Chemother 2005;56(suppl. S2):ii3-21.
2A.99 Harrison CJ et al. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including
serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
J Antimicrob Chemother 2009;63:511-9.
2A.100 Murphy TF et al. Moraxella catarrhalis, a human respiratory tract pathogen Clin Infect Dis 2009;49:
124-31.
2A.101 Mena LA et al. Randomized comparison of azithromycin and doxycycline for the treatment of Mycoplasma
genitalium-positive urethritis in men. Clin Infect Dis 2009;48:1649-54.
2A.102 Shahmanesh M et al. 2009 European guideline on the management of male non-gonococcal urethritis.
Int J STD AIDS 2009;20:458-64.
2A.103 Sánchez-Vargas et al. Mycoplasma pneumoniae – an emerging extra-pulmonary pathogen. Clin Microbiol
Infect 2008;14:105-15.
2A.104 Waites KB et al. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev
2004;17:697-728.
2A.105 Centers for Disease Control and Prevention (CDC). Update to CDC‘s sexually transmitted diseases
treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections.
Morb Mortal Wkly Rep 2007;56:332-6.
2A.106 Workowski KA et al. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to
strengthen prevention strategies. Ann Intern Med 2008;148:606-13.
2A.107 Newman LM et al. Update on the management of gonorrhea in adults in the United States. Clin
Infect Dis 2007;44(suppl. 3):S84-101.
2A.108 Bignell C. 2009 European (IUSTI/WHO) guideline on the diagnosis and treatment of gonorrhoea in
adults. Int J STD AIDS 2009;20:453-57.
2A.109 Jorgensen JH et al. Susceptibility of Neisseria meningitidis to 16 antimicrobial agents and characterization
of resistance mechanisms affecting some agents. J Clin Microbiol 2005;43:3162-71.
2A.110 Vázquez JA et al. Antibiotic resistant meningococci in Europe: any need to act? FEMS Microbiol Rev
2007;31:64-70.
2A.111 Stephens DS et al. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet
2007;369:2196-210.
2A.112 Lai CC et al. Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials
against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species. J Antimicrob
Chemother 2009;64:73-8.
2A.113 Jodlowski TZ et al. Linezolid for the treatment of Nocardia spp. infections. Ann Pharmacother 2007;
41:1694-9.
2A.114 Brown-Elliott BA et al. Clinical and laboratory features of the Nocardia spp. based on current molecular
taxonomy. Clin Microbiol Rev 2006;19:259-82.
2A.115 Gomez-Flores A et al. In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis. Antimicrob
Agents Chemother 2004;48:832-7.
2A.116 Lion C et al. Antimicrobial susceptibilities of Pasteurella strains isolated from humans. Int J Antimicrob
Agents 2006;27:290-3.
2A.117 Wybo I et al. Third Belgian multicentre survey of antibiotic susceptibility of anerobic bacteria. J Antimicrob
Chemother 2007;59:132-9.
2A.118 Glupczynski Y et al. Antimicrobial susceptibility of anaerobic bacteria in Belgium as determined by E-